0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BMS21008

Anti-TIM-3 monoclonal antibody

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: Anti-TIM-3 monoclonal antibody
    Indications: Tumors such as lung cancer,liver cancer, gastric carcinoma, cervical cancer, prostate cancer.
    Research phase: cell line screening
    Cooperation demands: Project authorization, transfer or co-development. (project’s company is seeking for external cooperation to accelate drug research and development.)
  • Highlights
    1. The highest developmental stage of TIM-3 antibody was phase II. Compared to other TIM-3 antibody in clinical phase, this project’s antibody’s binding epitope was not completely consistent and has unique characteristics ;
    2. This project’s antiboby could significantly inhibit tumor growth when in combination with PD-1 antibody, and the effectiveness was better than combination of Cobolimab and PD-1 antibody; (Cobolimab is the highest TIM-3 antibody in clinical phase development globaly)
    3. The indication was tumor which has huge market potential. Meanwhile,this project can be used alone or combined with anti PD-1 antibody, with the potential of overcoming the problem of PD-1 antibody resistance.
  • Project Introduction

    1. Drug type: Monoclonal antibody;

    2. Mechanism: TIM-3 inhibits anti-tumor by mediating T cell depletion. By combining TIM-3 on T cells and DCs, TIM-3 antibody can promote effector T cells (especially CD8+T cell ) to prolong the effect of anti-tumor, achieving the function of killing tumor;

    3. Indications: Tumors such as lung cancer,liver cancer, gastric carcinoma, cervical cancer, prostate cancer;

    4. Research phase: cell line screening;

    5. Research progress: The following studies have been completed : antibody construction and affinity, in vitro and in vivo functional validation,in vivo pharmacodynamics study. CMC development was started.

Comments (0)